Huda Y Zoghbi sold $1.3M of REGN
director at REGENERON PHARMACEUTICALS, INC.. 1,638 shares at an average of $781.33, traded Feb 19, 2026, filed Feb 23, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- +10Share of holdings soldSold 49% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.8%, 3m -18.7%, 6m +5.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001681643-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | MOption exercise Common Stock10b5-1 | +1,638 | $376.69 | $617k | 3,341 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -49 | $774.68 | $38k | 3,292 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -50 | $775.50 | $39k | 3,242 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -53 | $778.47 | $41k | 3,189 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -208 | $779.55 | $162k | 2,981 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -331 | $780.45 | $258k | 2,650 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -209 | $781.28 | $163k | 2,441 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -298 | $782.10 | $233k | 2,143 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -220 | $783.29 | $172k | 1,923 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $784.45 | $126k | 1,763 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -56 | $785.61 | $44k | 1,707 | Feb 23, 2026 |
| Feb 19, 2026 | SOpen-market sale Common Stock10b5-1 | -4 | $790.00 | $3,160 | 1,703 | Feb 23, 2026 |
| Feb 19, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -1,638 | $0.00 | $0 | 800 | Feb 23, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% | |
| 19Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.